New Study Shows Straticyte™ More Accurate Than Dysplasia Grading

Toronto, ON; February 2, 2017 – A newly published study shows Straticyte better defines the risk for developing oral squamous cell carcinoma than histopathological dysplasia grading alone. The study “Individualized Five-Year Risk Assessment for Oral Pre-malignant Progression to Cancer”was just published online in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology and can be accessed here.

Straticyte accurately predicts the patient’s probability of potential malignant lesions progressing to invasive oral cancer. Developed by Proteocyte Diagnostics, this laboratory service along with conventional histopathology gives oral maxillofacial surgeons a tool they need to provide a better level of care. It can be easily incorporated into clinical practice as no additional tissue samples are needed for assessment.

“We analyzed a cohort of 150 biopsy samples to test Straticyte as a prognostic tool,” said the study’s lead author, Jason Hwang, Proteocyte Product Development Manager. “Our study demonstrates that by using Straticyte, in conjunction with conventional histopathology, clinicians can provide a better individualized assessment of the five-year risk of progress from an early precancerous oral lesion to invasive cancer.”

The study was funded by Proteocyte and the Canadian Institutes of Health Research, CIHR Chair: Rx&D Collaborative Research Program using the Visiopharm analysis system.

“This study demonstrates the significant potential of Straticyte to address this global healthcare problem. Oral cancer is a very debilitating disease, causing severe facial disfigurement with a 5 year survival rate of 50%,” said John Davis, President and CEO of Proteocyte Diagnostics. “By diagnosing earlier and creating individualized treatment programs, the healthcare professional can improve the patient’s quality of life, reduce the number of deaths, and significantly reduce healthcare spending in this area.”

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology is required reading for anyone in the fields of oral surgery, oral medicine, oral pathology, oral radiology or advanced general practice dentistry. It is the only major dental journal that provides a practical and complete overview of the medical and surgical techniques of dental practice in four areas.

If you are an Oral Healthcare Professional and would like more information please contact Proteocyte Diagnostics at [email protected]

About Proteocyte Diagnostics New website! Proteocyte Diagnostics is a Canadian company that has developed a novel prognostic oral precancer laboratory service, Straticyte™ that objectively and accurately detects oral lesions at high risk of transforming to cancer and those that pose low risk. Early diagnosis of high risk lesions permits more effective and less traumatizing treatments. By identifying and treating oral cancer before it happens, clinicians can save lives, healthcare costs are reduced and quality of life of patients is improved. Identifying more accurately low risk pre-cancerous lesions avoids unnecessary surgeries and allows clinicians to monitor patients regularly for peace of mind.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Proteocyte management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.